

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxy clozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Levamisole / Oxy clozanide Formulation

Manufacturer or supplier's details

Company : MSD

Address : No. 485 Jing Tai Road
Pu Tuo District - Shanghai - China 200331

Telephone : +1-908-740-4000

Emergency telephone number : 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance : liquid
Colour : No data available
Odour : No data available

Suspected of damaging the unborn child. Toxic to aquatic life with long lasting effects.

GHS Classification

Reproductive toxicity : Category 2

Short-term (acute) aquatic hazard : Category 2

Long-term (chronic) aquatic hazard : Category 2

GHS label elements

Hazard pictograms :  

Signal word : Warning

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxy clozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

| | |
|--------------------------|---|
| Hazard statements | : H361d Suspected of damaging the unborn child. H411 Toxic to aquatic life with long lasting effects. |
| Precautionary statements | : Prevention: P203 Obtain, read and follow all safety instructions before use. P273 Avoid release to the environment. Response: P318 IF exposed or concerned, get medical advice. P391 Collect spillage. Storage: P405 Store locked up. Disposal: P501 Dispose of contents/ container to an approved waste disposal plant. |
| | |
| | |
| | |

Physical and chemical hazards

Not classified based on available information.

Health hazards

Suspected of damaging the unborn child.

Environmental hazards

Toxic to aquatic life. Toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|--------------------------|------------|-----------------------|
| Kaolin | 1332-58-7 | >= 1 < 10 |
| oxy clozanide | 2277-92-1 | >= 3 < 10 |
| levamisole hydrochloride | 16595-80-5 | >= 1 < 2.5 |
| Citric acid | 77-92-9 | >= 1 < 10 |

4. FIRST AID MEASURES

| | |
|----------------|--|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice. |
| If inhaled | : If inhaled, remove to fresh air. |

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxclozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

| | |
|---|---|
| In case of skin contact | Get medical attention. : In case of contact, immediately flush skin with soap and plenty of water. |
| In case of eye contact | Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. |
| If swallowed | Thoroughly clean shoes before reuse. : Flush eyes with water as a precaution. Get medical attention if irritation develops and persists. |
| Most important symptoms and effects, both acute and delayed | If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person. |
| Protection of first-aiders | : Suspected of damaging the unborn child. |
| Notes to physician | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| | : Treat symptomatically and supportively. |

5. FIREFIGHTING MEASURES

| | |
|---|---|
| Suitable extinguishing media | : Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical |
| Unsuitable extinguishing media | : None known. |
| Specific hazards during fire-fighting | : Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : Carbon oxides Chlorine compounds Nitrogen oxides (NO _x) |
| Specific extinguishing methods | : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area. |
| Special protective equipment for firefighters | : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment. |

6. ACCIDENTAL RELEASE MEASURES

| | |
|----------------------------------|--------------------------------------|
| Personal precautions, protection | : Use personal protective equipment. |
|----------------------------------|--------------------------------------|

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxy clozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

tive equipment and emergency procedures

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

- : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

- : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures

- : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

- : Use only with adequate ventilation.

Advice on safe handling

- : Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact

- : Oxidizing agents

Storage

Conditions for safe storage

- : Keep in properly labelled containers.
Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid

- : Do not store with the following product types:
Strong oxidizing agents

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxclozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parame- ters / Permissible concentration | Basis |
|---------------------------|------------|-------------------------------------|--|----------|
| Kaolin | 1332-58-7 | TWA (Respirable particulate matter) | 2 mg/m ³ | ACGIH |
| oxclozanide | 2277-92-1 | TWA | 0.4 mg/m ³ (OEB 2) | Internal |
| levamisole hydrochloride | 16595-80-5 | TWA | 20 µg/m ³ (OEB 3) | Internal |
| Further information: Skin | | Wipe limit | 200 µg/100 cm ² | Internal |

Engineering measures

- : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type
Eye/face protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hand protection

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxclozanide Formulation

Version 3.0 Revision Date: 2025/04/14 SDS Number: 5360070-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

| | |
|------------------|--|
| Material | : Chemical-resistant gloves |
| Remarks | : Consider double gloving. |
| Hygiene measures | : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

9. PHYSICAL AND CHEMICAL PROPERTIES

| | |
|--|---------------------|
| Appearance | : liquid |
| Colour | : No data available |
| Odour | : No data available |
| Odour Threshold | : No data available |
| pH | : No data available |
| Melting point/freezing point | : No data available |
| Initial boiling point and boiling range | : No data available |
| Flash point | : No data available |
| Evaporation rate | : No data available |
| Flammability (solid, gas) | : Not applicable |
| Flammability (liquids) | : No data available |
| Upper explosion limit / Upper flammability limit | : No data available |
| Lower explosion limit / Lower flammability limit | : No data available |
| Vapour pressure | : No data available |
| Relative vapour density | : No data available |
| Relative density | : No data available |
| Density | : No data available |

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxclozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-octanol/water

: Not applicable

Auto-ignition temperature

: No data available

Decomposition temperature

: No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties

: Not explosive

Oxidizing properties

: The substance or mixture is not classified as oxidizing.

Molecular weight

: No data available

Particle characteristics

Particle size : Not applicable

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxy clozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Components:

Kaolin:

| | |
|-----------------------|-----------------------------|
| Acute oral toxicity | : LD50 (Rat): > 5,000 mg/kg |
| Acute dermal toxicity | : LD50 (Rat): > 5,000 mg/kg |

oxy clozanide:

| | |
|---|--|
| Acute oral toxicity | : LD50 (Rat): 3,519 mg/kg Target Organs: Central nervous system |
| Acute toxicity (other routes of administration) | : LDLo (sheep): 10 mg/kg Application Route: Intravenous |

levamisole hydrochloride:

| | |
|---------------------------|--|
| Acute oral toxicity | : LD50 (Rat): 180 mg/kg LD50 (Mouse): 223 mg/kg LD50 (Rabbit): 458 mg/kg |
| Acute inhalation toxicity | : Remarks: No data available |
| Acute dermal toxicity | : Remarks: No data available |

Citric acid:

| | |
|-----------------------|---|
| Acute oral toxicity | : LD50 (Mouse): 5,400 mg/kg |
| Acute dermal toxicity | : LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity |

Skin corrosion/irritation

Not classified based on available information.

Components:

Kaolin:

| | |
|---------|---------------------------|
| Species | : Rabbit |
| Method | : OECD Test Guideline 404 |
| Result | : No skin irritation |

oxy clozanide:

| | |
|---------|---------------------------------------|
| Remarks | : Not classified due to lack of data. |
|---------|---------------------------------------|

levamisole hydrochloride:

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxyclozanide Formulation

Version 3.0 Revision Date: 2025/04/14 SDS Number: 5360070-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

||| Remarks : No data available

Citric acid:

||| Species : Rabbit
||| Method : OECD Test Guideline 404
||| Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Kaolin:

||| Species : Rabbit
||| Result : No eye irritation

oxyclozanide:

||| Remarks : Not classified due to lack of data.

levamisole hydrochloride:

||| Remarks : No data available

Citric acid:

||| Species : Rabbit
||| Result : Irritation to eyes, reversing within 21 days
||| Method : OECD Test Guideline 405

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

oxyclozanide:

||| Exposure routes : Dermal
||| Remarks : Not classified due to lack of data.

levamisole hydrochloride:

||| Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxclozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Components:

oxclozanide:

| | |
|-------------------------------------|---|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| | Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive |
| | Test Type: Mouse Lymphoma Result: positive |
| Genotoxicity in vivo | : Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative |
| | Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative |
| Germ cell mutagenicity - Assessment | : Weight of evidence does not support classification as a germ cell mutagen. |

levamisole hydrochloride:

| | |
|-----------------------|--|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| | Test Type: Chromosome aberration test in vitro Result: negative |

Citric acid:

| | |
|-----------------------|--|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| | Test Type: in vitro micronucleus test Result: positive |
| | Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| Genotoxicity in vivo | : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative |

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxyclozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Carcinogenicity

Not classified based on available information.

Components:

oxyclozanide:

||| Remarks : Not classified due to lack of data.

levamisole hydrochloride:

||| Species : Mouse
Application Route : Oral
Exposure time : 2 Years
NOAEL : 80 mg/kg body weight
Remarks : No significant adverse effects were reported

||| Species : Rat
Application Route : Oral
Exposure time : 2 Years
NOAEL : 40 mg/kg body weight
Remarks : No significant adverse effects were reported

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

oxyclozanide:

||| Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat, male and female
Application Route: Oral
General Toxicity - Parent: NOAEL: 25 - 35 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development
Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity - Parent: LOAEL: 75 - 100 mg/kg body weight
Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development
Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight
Result: No fetotoxicity, No teratogenic effects

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxy clozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

| | | |
|------------------------------------|---|--|
| | | Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: LOAEL: 80 - 160 mg/kg body weight Result: No fetotoxicity, No teratogenic effects, No effects on fertility |
| Effects on foetal development | : | Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 200 mg/kg body weight Result: No fetotoxicity, No teratogenic effects |
| | | Test Type: Development Species: Rat Application Route: Oral General Toxicity Maternal: LOAEL: 100 mg/kg body weight Result: No fetotoxicity, No teratogenic effects |
| | | Test Type: Development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 32 mg/kg body weight Result: Fetotoxicity, Skeletal malformations |
| Reproductive toxicity - Assessment | : | Suspected of damaging the unborn child. |
| levamisole hydrochloride: | | |
| Effects on fertility | : | Test Type: Three-generation reproduction toxicity study Species: Rat Application Route: Oral Result: No significant adverse effects were reported |
| Effects on foetal development | : | Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 20 mg/kg body weight Result: Fetotoxicity |
| | | Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 40 mg/kg body weight Result: Fetotoxicity |
| Reproductive toxicity - Assessment | : | Some evidence of adverse effects on development, based on animal experiments. |

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxyclozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Citric acid:

| | | |
|-------------------------------|---|---|
| Effects on foetal development | : | Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative |
|-------------------------------|---|---|

STOT - single exposure

Not classified based on available information.

Components:

oxyclozanide:

| | | |
|-----------------|---|-----------------------------|
| Exposure routes | : | Oral |
| Target Organs | : | Central nervous system |
| Assessment | : | May cause damage to organs. |

Citric acid:

| | | |
|------------|---|-----------------------------------|
| Assessment | : | May cause respiratory irritation. |
|------------|---|-----------------------------------|

STOT - repeated exposure

Not classified based on available information.

Components:

oxyclozanide:

| | | |
|---------------|---|--|
| Target Organs | : | Brain, Liver |
| Assessment | : | May cause damage to organs through prolonged or repeated exposure. |

levamisole hydrochloride:

| | | |
|---------------|---|--|
| Target Organs | : | Blood, Testis |
| Assessment | : | May cause damage to organs through prolonged or repeated exposure. |

Repeated dose toxicity

Components:

oxyclozanide:

| | | |
|-------------------|---|-------------------------------------|
| Species | : | Rat |
| NOAEL | : | 9 mg/kg |
| LOAEL | : | 44.5 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 3 Months |
| Target Organs | : | Brain, Liver, spleen, Adrenal gland |
| Symptoms | : | Liver effects |

| | | |
|---------|---|---------|
| Species | : | Dog |
| NOAEL | : | 5 mg/kg |

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxyclozanide Formulation

Version 3.0 Revision Date: 2025/04/14 SDS Number: 5360070-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

| | | |
|-------------------|---|--|
| LOAEL | : | 25 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 3 Months |
| Target Organs | : | Brain, Liver |
| Symptoms | : | blood effects, alteration in liver enzymes |

levamisole hydrochloride:

| | | |
|-------------------|---|-----------|
| Species | : | Rat |
| NOAEL | : | 2.5 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 18 Months |
| Target Organs | : | Testis |

| | | |
|-------------------|---|-----------|
| Species | : | Dog |
| LOAEL | : | 20 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 18 Months |
| Target Organs | : | Blood |

| | | |
|-------------------|---|----------|
| Species | : | Dog |
| LOAEL | : | 40 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 3 Months |

Citric acid:

| | | |
|-------------------|---|-------------|
| Species | : | Rat |
| NOAEL | : | 4,000 mg/kg |
| LOAEL | : | 8,000 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 10 Days |

Aspiration toxicity

Not classified based on available information.

Components:

oxyclozanide:

Not applicable

Experience with human exposure

Components:

oxyclozanide:

| | | |
|-----------|---|--|
| Ingestion | : | Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression |
|-----------|---|--|

levamisole hydrochloride:

| | | |
|-----------|---|--|
| Ingestion | : | Symptoms: Nausea, Vomiting, Headache, Dizziness, hypo- |
|-----------|---|--|

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxyclozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19



tension

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

oxyclozanide:

| | | |
|---|---|--|
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): 0.69 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 |
| M-Factor (Acute aquatic toxicity) | : | 1 |
| M-Factor (Chronic aquatic toxicity) | : | 1 |

levamisole hydrochloride:

| | | |
|---|---|---|
| Toxicity to fish | : | LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): 64 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 |

Citric acid:

| | | |
|---|---|--|
| Toxicity to fish | : | LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): 1,535 mg/l Exposure time: 24 h |

Persistence and degradability

Components:

oxyclozanide:

| | | |
|--------------------|---|--|
| Stability in water | : | Hydrolysis: 50 %(156 d) Method: OECD Test Guideline 111 |
|--------------------|---|--|

Citric acid:

| | | |
|------------------|---|---|
| Biodegradability | : | Result: Readily biodegradable. Biodegradation: 97 % Exposure time: 28 d Method: OECD Test Guideline 301B |
|------------------|---|---|

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxyclozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Bioaccumulative potential

Components:

oxyclozanide:

Partition coefficient: n-octanol/water : log Pow: 3.99
pH: 7
Method: OECD Test Guideline 107

Citric acid:

Partition coefficient: n-octanol/water : log Pow: -1.72

Mobility in soil

Components:

oxyclozanide:

Distribution among environmental compartments : log Koc: 4.83
Method: OECD Test Guideline 106

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(oxyclozanide)
Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxyclozanide Formulation

Version 3.0 Revision Date: 2025/04/14 SDS Number: 5360070-00013 Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

| | | |
|--|---|---|
| | | (oxyclozanide) |
| Class | : | 9 |
| Packing group | : | III |
| Labels | : | Miscellaneous |
| Packing instruction (cargo aircraft) | : | 964 |
| Packing instruction (passenger aircraft) | : | 964 |
| Environmentally hazardous | : | yes |
| IMDG-Code | | |
| UN number | : | UN 3082 |
| Proper shipping name | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxyclozanide) |
| Class | : | 9 |
| Packing group | : | III |
| Labels | : | 9 |
| EmS Code | : | F-A, S-F |
| Marine pollutant | : | yes |

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

GB 6944/12268

| | | |
|----------------------|---|---|
| UN number | : | UN 3082 |
| Proper shipping name | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxyclozanide) |
| Class | : | 9 |
| Packing group | : | III |
| Labels | : | 9 |
| Marine pollutant | : | no |

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

Regulations on Safety Management of Hazardous Chemicals

| | | |
|----------------------------------|---|---|
| Catalogue of Hazardous Chemicals | : | This product is not listed in the catalogue of hazardous chemicals, but it meets the definition of hazardous chemicals and its principles of determination. |
|----------------------------------|---|---|

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxclozanide Formulation

Version 3.0 Revision Date: 2025/04/14 SDS Number: 5360070-00013 Date of last issue: 2024/09/28 Date of first issue: 2019/12/19

Identification of Major Hazard Installations for Hazardous Chemicals (GB 18218) : Not listed

Hazardous Chemicals for Priority Management under SAWS : Not listed

Catalogue of Specially Controlled Hazardous Chemicals : Not listed

List of Explosive Precursors : Not listed

Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import and Export : Not listed

Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

Regulations of Ozone Depleting Substances Management

List of Controlled Ozone Depleting Substances Import and Export : Not listed

List of Controlled Ozone Depleting Substances : Not listed

Environmental Protection Law

List of Priority Controlled Chemicals : Not listed

List of Key Controlled New Pollutants : Not listed

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2025/04/14

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxy clozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Levamisole / Oxclozanide Formulation

Version
3.0

Revision Date:
2025/04/14

SDS Number:
5360070-00013

Date of last issue: 2024/09/28
Date of first issue: 2019/12/19

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN